Table 5 Adjusted odds ratio of adverse pregnancy outcomes among women who received metformin monotherapy in switching group and metformin group as compared to insulin therapy
Cohort | Switching Group (n = 273)a | Metformin Group (n = 596)a |
|---|---|---|
Maternal outcome | ||
Primary cesarean section | 1.06 (0.73–1.54) | 0.57 (0.40–0.82) |
Pregnancy-related hypertension | 1.20 (0.78–1.86) | 0.81 (0.53–1.23) |
Preeclampsia | 1.17 (0.70–1.95) | 0.83 (0.51–1.34) |
Fetal outcome | ||
Preterm birth (< 37 week) | 1.07 (0.73–1.58) | 0.97 (0.64–1.48) |
Very preterm delivery (< 32 weeks) | 0.51 (0.18–1.49) | 0.93 (0.38–2.27) |
Low birth weight (< 2500 g) | 1.14 (0.64–2.04) | 1.33 (0.76–2.34) |
High birth weight (> 4000 g) | 1.60 (0.98–2.60) | 0.84 (0.49–1.45) |
Small for gestational age | – | 1.00 (0.51–1.97) |
Large for gestational age | 1.54 (1.05–2.25) | 0.86 (0.60–1.23) |
Congenital malformations | 0.72 (0.38–1.35) | 0.47 (0.25–0.89) |
Apgar score < 7 at 5 min | – | 1.48 (0.28–7.79) |
Stillbirth | – | 0.79 (0.26–2.39) |